BioWorld - Tuesday, July 28, 2026 See today's BioWorld Home $170M banked, Bioage phase II to test GLP-1/apelin combo To read the full story, subscribe or sign in
51-OR: a phase 2, randomized, double-blind, placebo-controlled, dose-finding study of BI 456906 in people with overweight/obesity
Camurus has the option to collect up to USD 290 million in upfront, development, and regulatory milestone payments, as well as USD 580 million in sales-based milestone payments and tiered mid-single digit royalties on worldwide net product sales
Quick Answer: Guidelines recommend considering GLP-1 receptor agonists for weight regain after bariatric surgery when BMI remains 27 kg/m with comorbidities or 30 kg/m, lifestyle modifications are insufficient, and no anatomical complications require surgical revision
A critical perspective on the supplementation of Akkermansia muciniphila : Benefits and harms